A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

Abstract Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized imm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Flávia Sousa, Andrea Cruz, Pedro Fonte, Inês Mendes Pinto, Maria Teresa Neves-Petersen, Bruno Sarmento
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d53d29d91a274412b03b006cf9a016af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d53d29d91a274412b03b006cf9a016af
record_format	dspace
spelling	oai:doaj.org-article:d53d29d91a274412b03b006cf9a016af2021-12-02T12:30:45ZA new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles10.1038/s41598-017-03959-42045-2322https://doaj.org/article/d53d29d91a274412b03b006cf9a016af2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03959-4https://doaj.org/toc/2045-2322Abstract Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized immunoglobulin IgG1 used in antiangiogenic therapies due to its capacity to inhibit the interaction between vascular endothelial growth factor and its receptor. However, bevacizumab-based antiangiogenic therapy is not always effective due to poor treatment compliance associated to multiples administrations and drug resistance. In this work, we show a promising strategy of encapsulating bevacizumab to protect and deliver it, in a controlled manner, increasing the time between administrations and formulation shelf-life. Nanoencapsulation of bevacizumab represents a significant advance for selective antiangiogenic therapies since extracellular, cell surface and intracellular targets can be reached. The present study shows that bevacizumab-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles does not impair its native-like structure after encapsulation and fully retain the bioactivity, making this nanosystem a new paradigm for the improvement of angiogenic therapy.Flávia SousaAndrea CruzPedro FonteInês Mendes PintoMaria Teresa Neves-PetersenBruno SarmentoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Flávia Sousa Andrea Cruz Pedro Fonte Inês Mendes Pinto Maria Teresa Neves-Petersen Bruno Sarmento A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
description	Abstract Monoclonal antibodies have deserved a remarkable interest for more than 40 years as a vital tool for the treatment of various diseases. Still, there is a raising interest to develop advanced monoclonal antibody delivery systems able to tailor pharmacokinetics. Bevacizumab is a humanized immunoglobulin IgG1 used in antiangiogenic therapies due to its capacity to inhibit the interaction between vascular endothelial growth factor and its receptor. However, bevacizumab-based antiangiogenic therapy is not always effective due to poor treatment compliance associated to multiples administrations and drug resistance. In this work, we show a promising strategy of encapsulating bevacizumab to protect and deliver it, in a controlled manner, increasing the time between administrations and formulation shelf-life. Nanoencapsulation of bevacizumab represents a significant advance for selective antiangiogenic therapies since extracellular, cell surface and intracellular targets can be reached. The present study shows that bevacizumab-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles does not impair its native-like structure after encapsulation and fully retain the bioactivity, making this nanosystem a new paradigm for the improvement of angiogenic therapy.
format	article
author	Flávia Sousa Andrea Cruz Pedro Fonte Inês Mendes Pinto Maria Teresa Neves-Petersen Bruno Sarmento
author_facet	Flávia Sousa Andrea Cruz Pedro Fonte Inês Mendes Pinto Maria Teresa Neves-Petersen Bruno Sarmento
author_sort	Flávia Sousa
title	A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
title_short	A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
title_full	A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
title_fullStr	A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
title_full_unstemmed	A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
title_sort	new paradigm for antiangiogenic therapy through controlled release of bevacizumab from plga nanoparticles
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/d53d29d91a274412b03b006cf9a016af
work_keys_str_mv	AT flaviasousa anewparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT andreacruz anewparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT pedrofonte anewparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT inesmendespinto anewparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT mariateresanevespetersen anewparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT brunosarmento anewparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT flaviasousa newparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT andreacruz newparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT pedrofonte newparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT inesmendespinto newparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT mariateresanevespetersen newparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles AT brunosarmento newparadigmforantiangiogenictherapythroughcontrolledreleaseofbevacizumabfromplgananoparticles
_version_	1718394363503968256

A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles

Ejemplares similares